Get started
PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION)PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION)PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION)

PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION)

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

0QSS fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0QSS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company